Multifocal Motor Neuropathy (MMN)

A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN)

NCT00701662 | PHASE 2 | INTERVENTIONAL

The objective of this study is to assess efficacy, safety, and convenience of purified human antibodies administered under the skin in the treatment of MMN patients.

3 Sites

8 Participants

Recruiting

18 Years to 65 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

San Raffaele Hospital

Milan,Italy

Inselspital

Bern,Switzerland

Dept. Clinical Immunology, Oxford Radcliffe Hospitals

Oxford,United Kingdom

Study Eligibility Criteria

Inclusion Criteria

* Patients with documented clinical diagnosis and electrophysiological evidence of MMN
* Patients who have previously responded to intravenous immunoglobulin (IVIG) and have been on stable treatment with IVIG for at least 12 weeks prior to screening
* Patients treated with the equivalent of ≥0.4g/kg body weight (bw) IVIG per month
* Provision of informed consent by patient

Exclusion Criteria

* Aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) concentration \>2.5 times the upper normal limit (UNL)
* Creatinine concentration \>1.5 times the UNL
* Known allergic reactions to blood products
* Any skin disease interfering with the assessment of injection site reactions
* Any other medical condition, which in the opinion of the investigator, might interfere with successful completion of the protocol
* Any condition likely to interfere with the evaluation of the study drug or satisfactory conduct of the trial
* Participation in a study with an investigational drug within three months prior to enrolment
* Patients treated with the equivalent of \>2.0g/kg bw IVIG per month

Additional Studies

Additional studies can be found at ClinicalTrials.gov